Last Updated: June 9, 2026

Details for New Drug Application (NDA): 020738

✉ Email this page to a colleague

NDA 020738 describes TEVETEN, which is a drug marketed by Abbvie and is included in two NDAs. Additional details are available on the TEVETEN profile page.

The generic ingredient in TEVETEN is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.

Summary for 020738

Tradename:	TEVETEN
Applicant:	Abbvie
Ingredient:	eprosartan mesylate
Patents:	0

Profile for product number 004

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	EQ 300MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Dec 22, 1997	TE:		RLD:	No

Profile for product number 005

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	EQ 400MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Dec 22, 1997	TE:		RLD:	Yes

Profile for product number 006

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	EQ 600MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	May 27, 1999	TE:		RLD:	Yes

Expired US Patents for NDA 020738

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-004	Dec 22, 1997	5,185,351	⤷ Start Trial
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999	5,656,650	⤷ Start Trial
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997	5,185,351	⤷ Start Trial
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-004	Dec 22, 1997	5,656,650	⤷ Start Trial
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999	5,185,351	⤷ Start Trial
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997	5,656,650	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.